Cell-surface glycans terminating in β-linked galactose (β-galactosyl glycans)

Cell-surface glycans terminating in β-linked galactose are complex carbohydrate structures found on the exterior of cell membranes, attached to proteins or lipids. These glycans serve as critical recognition motifs for a family of proteins called galectins, which play pivotal roles in cell-cell adhesion, migration, and immune system regulation (Source: NCBI). In various pathological conditions, particularly cancer, the expression and branching of these β-galactosyl-terminated glycans are often altered, promoting tumor metastasis and helping cancer cells evade immune detection (Source: Nature Reviews Cancer). Therapeutic strategies targeting these glycans or their interactions typically involve galectin inhibitors, which aim to block the binding of galectins to these terminal sugar residues (Source: PubMed). Additionally, certain toxins and pathogens exploit these glycans as entry receptors into host cells (Source: PubMed). Understanding the specific patterns of these glycans is essential for developing targeted therapies and diagnostic biomarkers in oncology and immunology (Source: NCBI).

Other names

Terminal β-galactose residuesβ-galactoside-terminated glycansGal-terminated glycansType 1 and Type 2 lactosamine chains

These glycans act as ligands for endogenous lectins (galectins) and exogenous toxins or pathogens; therapeutic agents may bind directly to the glycans to block entry or inhibit the partner protein (e.g., galectin) to prevent lattice formation and signaling (Source: Nature Reviews Cancer).